OncoSec Medical (NASDAQ:ONCS) and MusclePharm (OTCMKTS:MSLP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitability.

Institutional and Insider Ownership

11.4% of OncoSec Medical shares are owned by institutional investors. Comparatively, 10.2% of MusclePharm shares are owned by institutional investors. 7.6% of OncoSec Medical shares are owned by insiders. Comparatively, 60.7% of MusclePharm shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

OncoSec Medical has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, MusclePharm has a beta of 2.97, meaning that its share price is 197% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for OncoSec Medical and MusclePharm, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OncoSec Medical 0 2 2 0 2.50
MusclePharm 0 0 0 0 N/A

OncoSec Medical presently has a consensus target price of $4.00, suggesting a potential upside of 479.71%. Given OncoSec Medical’s higher probable upside, analysts clearly believe OncoSec Medical is more favorable than MusclePharm.

Valuation & Earnings

This table compares OncoSec Medical and MusclePharm’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OncoSec Medical N/A N/A -$39.13 million N/A N/A
MusclePharm $102.15 million 0.13 -$10.97 million N/A N/A

MusclePharm has higher revenue and earnings than OncoSec Medical.

Profitability

This table compares OncoSec Medical and MusclePharm’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OncoSec Medical N/A -151.71% -123.34%
MusclePharm -7.41% N/A -31.87%

Summary

MusclePharm beats OncoSec Medical on 6 of the 10 factors compared between the two stocks.

OncoSec Medical Company Profile

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response in Phase 1 and 2 clinical trials for metastatic melanoma and triple-negative breast cancer. The company has also completed Phase II studies in metastatic melanoma (OMS-I100) and merkel cell carcinoma (OMS-I110). OncoSec Medical Incorporated has an investigator-sponsored clinical trial with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte (OMS-I102); and a clinical trial collaboration and drug supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of its ImmuoPulse IL-12 with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a registration-directed Phase 2b clinical trial referred to as PISCES. This trial would evaluate the combination of therapies in patients with unresectable metastatic melanoma who have progressed. It also has a research collaboration with Avacta Group plc for gene delivery of therapeutic affimers. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.

MusclePharm Company Profile

MusclePharm Corporation develops, manufactures, markets, and distributes nutritional supplements in the United States and internationally. It offers a range of powders, capsules, tablets, and gels. The company's MusclePharm brand product portfolio include Combat protein powder and Combat crunch protein bars; essentials supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products; and non-genetically modified organism sports performance products with organic ingredients, plant-based proteins, and natural caffeine sources for use in the various stages of the workout. It also provides FitMiss sports nutrition products, which are designed and formulated primarily for women lifestyle to cover various needs, including weight management, lean muscle mass, body composition, and general health and wellness. MusclePharm Corporation sells its products to various fitness enthusiasts, such as professional, combat sport, weight training, bodybuilding, running, and various team and individual sports, as well as individuals who lead an active lifestyle. The company was founded in 2006 and is headquartered in Burbank, California.

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.